COMMUNIQUÉS West-GlobeNewswire

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
04/04/2024
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema [...]
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
04/04/2024
--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : [...]
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
04/04/2024
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the [...]
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
04/04/2024
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in [...]
Oculis to Participate at Upcoming April Investor Conferences
04/04/2024
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that [...]
Notice convening the Annual General Meeting in BioPorto A/S
04/04/2024
April 4, 2024 Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on [...]
Medigene AG Secures European Patent for its iM-TCR Technology
04/04/2024
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today [...]
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
04/04/2024
Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing [...]
Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE
04/04/2024
Le test d’acide nucléique in vitro de Grifols détecte quatre types d’arbovirus, contribuant ainsi à la diminution du risque d’infections transmises par transfusion* Les arbovirus constituent une menace émergente [...]
Correction: BioPorto Announces Annual Results for 2023
04/04/2024
Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto [...]
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
04/04/2024
GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that [...]
Pharming Group announces the 2024 Annual General Meeting of Shareholders
04/04/2024
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) [...]
BioPorto Announces Annual Results for 2023
04/04/2024
April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
04/04/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
04/04/2024
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “ [...]
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
04/04/2024
New biomarker may facilitate monitoring T1D patients’ health Increase in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG [...]
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/04/2024
Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with [...]
Opthea Appoints Sujal Shah to the Board of Directors
03/04/2024
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE [...]
Palisade Bio Announces 1-for-15 Reverse Stock Split
03/04/2024
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]

Pages